{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:03:28Z","timestamp":1789675408378,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011272","name":"FP7-HEALTH","doi-asserted-by":"crossref","award":["260576"],"award-info":[{"award-number":["260576"]}],"id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12888-018-1884-7","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T20:59:25Z","timestamp":1539205165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-7052","authenticated-orcid":false,"given":"Suzanne","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K. C.","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Banaschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Buitelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Carucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Coghill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Danckaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Falissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Garas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"H\u00e4ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Hollis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Inglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kovshoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Liddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Mechler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Sonuga-Barke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zuddas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"1884_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fifth ed. Arlington: Americal Psychiatric Publishing; 2013.","edition":"Fifth"},{"issue":"6","key":"1884_CR2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","volume":"164","author":"G Polanczyk","year":"2007","unstructured":"Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942\u20138.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1884_CR3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/ije\/dyt261","volume":"43","author":"GV Polanczyk","year":"2014","unstructured":"Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43(2):434\u201342.","journal-title":"Int J Epidemiol"},{"key":"1884_CR4","unstructured":"National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE Clinical Guideline 87 2018. Available from \n                    https:\/\/www.nice.org.uk\/guidance\/ng87\/resources\/attention-deficit-hyperactivity-disorder-diagnosis-andmanagement-pdf-1837699732933\n                    \n                  . Accessed 23 Sept 2018."},{"issue":"9","key":"1884_CR5","first-page":"994","volume":"47","author":"SV Faraone","year":"2008","unstructured":"Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(9):994\u20131009.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"14","key":"1884_CR6","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMp068049","volume":"354","author":"SE Nissen","year":"2006","unstructured":"Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"1884_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jpeds.2010.04.025","volume":"157","author":"J Biederman","year":"2010","unstructured":"Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr. 2010;157(4):635\u201340, 40 e1.","journal-title":"J Pediatr"},{"issue":"4","key":"1884_CR8","doi-asserted-by":"publisher","first-page":"e935","DOI":"10.1542\/peds.2014-0428","volume":"134","author":"EB Harstad","year":"2014","unstructured":"Harstad EB, Weaver AL, Katusic SK, Colligan RC, Kumar S, Chan E, et al. ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics. 2014;134(4):e935\u201344.","journal-title":"Pediatrics"},{"issue":"5","key":"1884_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/01.chi.0000205710.01690.d4","volume":"45","author":"TJ Spencer","year":"2006","unstructured":"Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B, et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry. 2006;45(5):527\u201337.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"1884_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/chi.0b013e3180686d7e","volume":"46","author":"JM Swanson","year":"2007","unstructured":"Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015\u201327.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"1884_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/01.chi.0000199026.91699.20","volume":"45","author":"A Charach","year":"2006","unstructured":"Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry. 2006;45(4):415\u201321.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"1884_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5694\/mja12.10931","volume":"198","author":"AS Poulton","year":"2013","unstructured":"Poulton AS, Melzer E, Tait PR, Garnett SP, Cowell CT, Baur LA, et al. Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. Med J Aust. 2013;198(1):29\u201332.","journal-title":"Med J Aust"},{"issue":"11","key":"1884_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.4088\/JCP.13l08580","volume":"74","author":"H Peyre","year":"2013","unstructured":"Peyre H, Hoertel N, Cortese S, Acquaviva E, Limosin F, Delorme R. Long-term effects of ADHD medication on adult height: results from the NESARC. J Clin Psychiatry. 2013;74(11):1123\u20134.","journal-title":"J Clin Psychiatry"},{"key":"1884_CR14","doi-asserted-by":"publisher","first-page":"h5203","DOI":"10.1136\/bmj.h5203","volume":"351","author":"OJ Storebo","year":"2015","unstructured":"Storebo OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. Methylphenidate for attention-deficit\/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203.","journal-title":"BMJ"},{"issue":"4","key":"1884_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1542\/peds.2013-3427","volume":"133","author":"BS Schwartz","year":"2014","unstructured":"Schwartz BS, Bailey-Davis L, Bandeen-Roche K, Pollak J, Hirsch AG, Nau C, et al. Attention deficit disorder, stimulant use, and childhood body mass index trajectory. Pediatrics. 2014;133(4):668\u201376.","journal-title":"Pediatrics"},{"key":"1884_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/7854_2011_154","volume":"9","author":"S Cortese","year":"2012","unstructured":"Cortese S, Vincenzi B. Obesity and ADHD: clinical and neurobiological implications. Curr Top Behav Neurosci. 2012;9:199\u2013218.","journal-title":"Curr Top Behav Neurosci"},{"issue":"4","key":"1884_CR17","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1089\/cap.2010.0113","volume":"22","author":"T Hanc","year":"2012","unstructured":"Hanc T, Cieslik J, Wolanczyk T, Gajdzik M. Assessment of growth in pharmacological treatment-naive polish boys with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012;22(4):300\u20136.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"6","key":"1884_CR18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1089\/cap.2014.0020","volume":"24","author":"S Dalsgaard","year":"2014","unstructured":"Dalsgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M. Cardiovascular safety of stimulants in children with attention-deficit\/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol. 2014;24(6):302\u201310.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"20","key":"1884_CR19","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1056\/NEJMoa1110212","volume":"365","author":"WO Cooper","year":"2011","unstructured":"Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896\u2013904.","journal-title":"N Engl J Med"},{"issue":"24","key":"1884_CR20","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2011.1830","volume":"306","author":"LA Habel","year":"2011","unstructured":"Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673\u201383.","journal-title":"JAMA"},{"issue":"6","key":"1884_CR21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1542\/peds.2010-3371","volume":"127","author":"H Schelleman","year":"2011","unstructured":"Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127(6):1102\u201310.","journal-title":"Pediatrics"},{"issue":"4","key":"1884_CR22","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1016\/j.ijcard.2013.04.169","volume":"168","author":"M Mazza","year":"2013","unstructured":"Mazza M, D'Ascenzo F, Davico C, Biondi-Zoccai B, Fratie G, Romagnolig E, et al. Drugs for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden death in children: a meta-analysis of observational studies. Int J Cardiol. 2013;168(4):4320\u20131. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2013.04.169\n                    \n                  . Epub May 11.","journal-title":"Int J Cardiol"},{"key":"1884_CR23","doi-asserted-by":"publisher","first-page":"e4627","DOI":"10.1136\/bmj.e4627","volume":"345","author":"AG Winterstein","year":"2012","unstructured":"Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ. 2012;345:e4627.","journal-title":"BMJ"},{"issue":"1","key":"1884_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00787-010-0140-6","volume":"20","author":"J Graham","year":"2011","unstructured":"Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20(1):17\u201337.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"1","key":"1884_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1017\/S1047951111000928","volume":"22","author":"RM Hamilton","year":"2012","unstructured":"Hamilton RM, Rosenthal E, Hulpke-Wette M, Graham JG, Sergeant J, European network of hyperkinetic D. Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European network on hyperactivity disorders work group, European attention deficit hyperactivity disorder guidelines group on attention deficit hyperactivity disorder drug safety meeting. Cardiol Young. 2012;22(1):63\u201370.","journal-title":"Cardiol Young"},{"key":"1884_CR26","unstructured":"European Medicines Agency. EMEA 2010 Priorities for Drug Safety Research. Long-term effects in children and in young adults of methylphenidate in the treatment of attention deficit hyperactivity disorder (ADHD). Available from \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2010\/03\/WC500076318.pdf\n                    \n                  . Accessed 10\/11\/2015."},{"issue":"Suppl 1","key":"1884_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00787-008-1006-z","volume":"17","author":"M Huss","year":"2008","unstructured":"Huss M, Holling H, Kurth BM, Schlack R. How often are German children and adolescents diagnosed with ADHD? Prevalence based on the judgment of health care professionals: results of the German health and examination survey (KiGGS). Eur Child Adolesc Psychiatry. 2008;17(Suppl 1):52\u20138.","journal-title":"Eur Child Adolesc Psychiatry."},{"key":"1884_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/1471-2458-8-196","volume":"8","author":"BM Kurth","year":"2008","unstructured":"Kurth BM, Kamtsiuris P, Holling H, Schlaud M, Dolle R, Ellert U, et al. The challenge of comprehensively mapping children's health in a nation-wide health survey: design of the German KiGGS-study. BMC Public Health. 2008;8:196.","journal-title":"BMC Public Health"},{"issue":"6","key":"1884_CR29","doi-asserted-by":"publisher","first-page":"e000477","DOI":"10.1136\/bmjopen-2011-000477","volume":"2","author":"Hildtraud Knopf","year":"2012","unstructured":"Knopf H, Holling H, Huss M, Schlack R. Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: results of the German Health Interview and Examination Survey (KiGGS). BMJ Open. 2012;2:e000477. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2011-000477\n                    \n                  .","journal-title":"BMJ Open"},{"issue":"5\u20136","key":"1884_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00103-007-0216-8","volume":"50","author":"H Holling","year":"2007","unstructured":"Holling H, Kamtsiuris P, Lange M, Thierfelder W, Thamm M, Schlack R. The German health interview and examination survey for children and adolescents (KiGGS): study management and conduct of fieldwork. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;50(5\u20136):557\u201366.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"4","key":"1884_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/ejcn.2010.8","volume":"64","author":"AS Rosario","year":"2010","unstructured":"Rosario AS, Kurth BM, Stolzenberg H, Ellert U, Neuhauser H. Body mass index percentiles for children and adolescents in Germany based on a nationally representative sample (KiGGS 2003-2006). Eur J Clin Nutr. 2010;64(4):341\u20139.","journal-title":"Eur J Clin Nutr"},{"issue":"4","key":"1884_CR32","doi-asserted-by":"publisher","first-page":"e978","DOI":"10.1542\/peds.2010-1290","volume":"127","author":"HK Neuhauser","year":"2011","unstructured":"Neuhauser HK, Thamm M, Ellert U, Hense HW, Rosario AS. Blood pressure percentiles by age and height from nonoverweight children and adolescents in Germany. Pediatrics. 2011;127(4):e978\u201388.","journal-title":"Pediatrics"},{"issue":"2","key":"1884_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/03014460.2010.521193","volume":"38","author":"AS Rosario","year":"2011","unstructured":"Rosario AS, Schienkiewitz A, Neuhauser H. German height references for children aged 0 to under 18 years compared to WHO and CDC growth charts. Ann Hum Biol. 2011;38(2):121\u201330.","journal-title":"Ann Hum Biol"},{"issue":"38","key":"1884_CR34","first-page":"642","volume":"108","author":"W N\u00fctzenadel","year":"2011","unstructured":"N\u00fctzenadel W. Failure to thrive in childhood. Dtsch \u00c4rztebl Int. 2011;108(38):642\u20139.","journal-title":"Dtsch \u00c4rztebl Int"},{"issue":"9","key":"1884_CR35","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1097\/HJH.0b013e32832f4f6b","volume":"27","author":"E Lurbe","year":"2009","unstructured":"Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27(9):1719\u201342.","journal-title":"J Hypertens"},{"issue":"2","key":"1884_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1055\/s-0030-1261893","volume":"41","author":"H Zhang","year":"2010","unstructured":"Zhang H, Du M, Zhuang S. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics. 2010;41(2):55\u20139.","journal-title":"Neuropediatrics"},{"issue":"5","key":"1884_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1586\/14737175.2014.904748","volume":"14","author":"S Cortese","year":"2014","unstructured":"Cortese S, Castellanos FX. The relationship between ADHD and obesity: implications for therapy. Expert Rev Neurother. 2014;14(5):473\u20139.","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"1884_CR38","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1097\/chi.0b013e31806ad1d7","volume":"46","author":"SV Faraone","year":"2007","unstructured":"Faraone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1138\u201347.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"1884_CR39","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40264-014-0201-8","volume":"37","author":"GA Awudu","year":"2014","unstructured":"Awudu GA, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update. Drug Saf. 2014;37(9):661\u201376.","journal-title":"Drug Saf"},{"issue":"9349","key":"1884_CR40","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903\u201313.","journal-title":"Lancet"},{"issue":"Supplement 2","key":"1884_CR41","first-page":"555","volume":"114","author":"The Fourth Report on the Diagnosis","year":"2004","unstructured":"The Fourth Report on the Diagnosis. Evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(Supplement 2):555\u201376.","journal-title":"Pediatrics"},{"issue":"5\u20136","key":"1884_CR42","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00103-007-0246-2","volume":"50","author":"R Schlack","year":"2007","unstructured":"Schlack R, Holling H, Kurth BM, Huss M. The prevalence of attention-deficit\/hyperactivity disorder (ADHD) among children and adolescents in Germany. Initial results from the German health interview and examination survey for children and adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;50(5\u20136):827\u201335.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz."},{"key":"1884_CR43","doi-asserted-by":"publisher","first-page":"15020","DOI":"10.1038\/nrdp.2015.20","volume":"1","author":"SV Faraone","year":"2015","unstructured":"Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. Attention-deficit\/hyperactivity disorder. Nat Rev Dis Primers. 2015;1:15020.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"1884_CR44","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/jcpp.12164","volume":"55","author":"Z Chang","year":"2014","unstructured":"Chang Z, Lichtenstein P, Halldner L, D'Onofrio B, Serlachius E, Fazel S, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014;55(8):878\u201385.","journal-title":"J Child Psychol Psychiatry"},{"issue":"21","key":"1884_CR45","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","volume":"367","author":"P Lichtenstein","year":"2012","unstructured":"Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006\u201314.","journal-title":"N Engl J Med"},{"issue":"1","key":"1884_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1542\/peds.2014-1738","volume":"135","author":"KK Man","year":"2015","unstructured":"Man KK, Chan EW, Coghill D, Douglas I, Ip P, Leung LP, et al. Methylphenidate and the risk of trauma. Pediatrics. 2015;135(1):40\u20138.","journal-title":"Pediatrics"},{"issue":"3","key":"1884_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/jcpp.12036","volume":"54","author":"S Cortese","year":"2013","unstructured":"Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54(3):227\u201346.","journal-title":"J Child Psychol Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-018-1884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-018-1884-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-018-1884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T19:18:19Z","timestamp":1570735099000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-018-1884-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1884"],"URL":"https:\/\/doi.org\/10.1186\/s12888-018-1884-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]},"assertion":[{"value":"26 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The KiGGS survey was approved by the <i>Charit\u00e9 Universit\u00e4tsmedizin, Berlin<\/i> ethics committee (no.: 101\/2000) of the Virchow Hospital, Humboldt University Berlin and Federal Office for the Protection of the Data (no.: IV-401\/008#0008). Written, informed consent was obtained prior to each interview and examination from the children\u2019s parents and the children themselves if they were aged \u226514\u00a0years.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ESB: Financial.Speaker fees, consultancy, research funding and conference support from Shire Pharma. Speaker fees from American University of Beirut, Janssen Cilag, Consultancy from Neurotech solutions, Copenhagen University and Berhanderling, Skolerne, KU Leuven. Book royalties from OUP and Jessica Kingsley. Financial support received from Arrhus Univeristy and Ghent University for visiting Professorship. Grants awarded from MRC, ESRC, Wellcome Trust, Solent NHS Trust, European Union, Child Health Research Foundation New Zealand, NIHR, Nuffield Foundation, Fonds Wetenschappelijk Onderzoek-Vlaanderen (FWO), MQ \u2013 Transforming Mental health. Editor-in-Chief JCPP \u2013 supported by a buy-out of time to University of Southampton and personal Honorarium.Non-financial.Member of the European ADHD Guidelines Group.TB: Dr. Banaschewski served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Medice, Novartis, Oxford outcomes, PCM scientific, Shire and Viforpharma. He received conference support or speaker\u2019s fee by Medice, Novartis and Shire. He is\/has been involved in clinical trials conducted by Shire & Viforpharma. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is unrelated to the above grants and relationships.JB: Jan K Buitelaar has been in the past 3\u00a0years a consultant to \/ member of advisory board of \/.and\/or speaker for Janssen Cilag BV, Eli Lilly, Lundbeck, Shire, Roche, Medice, Novartis,and Servier. He has received research support from Roche and Vifor. He is not an employee.of any of these companies, and not a stock shareholder of any of these companies. He has no.other financial or material support, including expert testimony, patents, royalties.SC: During the last three years collaboration within projects from the European Union (7th Framework Program) and collaboration as sub-investigator in sponsored clinical trials by Shire Pharmaceutical Company. Travel support from Shire Pharmaceutical Company.DC: Prof. Coghill reports grants from European Commission, during the conduct of the study; grants and personal fees from Shire, personal fees from Eli Lilly, grants from Vifor, personal fees from Novartis, personal fees from Oxford University Press, other than the EC grants these are all outside the submitted work.MD: MD is a member of the European ADHD Guideline Group (EAGG) and holds grants from the European Union FP7 programme.BF: The author declares that they have no conflict of interest.PG: The author declares that they have no conflict of interest.CH: Grants from European Union FP7 programme, H2020, National Institute of Health Research (NIHR) and Medical Research Council (MRC) during the conduct of the study; CH is a member of the European ADHD Guideline Group (EAGG) and NICE ADHD Guideline Committee.SI: The author declares that they have no conflict of interest.HK: The author declares that they have no conflict of interest.EL: The author declares that they have no conflict of interest.K KC M: The author declares that they have no conflict of interest.KM: The author declares that they have no conflict of interest.SM: Dr. McCarthy has received speaker\u2019s fee, travel support and research support from Shire.AN: The author declares that they have no conflict of interest.PN: The author declares that they have no conflict of interest.ER: The author declares that they have no conflict of interest.RS: The author declares that they have no conflict of interest.AH: A. H\u00e4ge received speakers\u2019 fees, was on advisory boards or has been involved in clinical trials by Shire, Janssen-Cilag, Otsuka, Lundbeck and Servier.AZ: Dr. Zuddas served in an advisory or consultancy role for Angelini, Lundbeck, Otsuka, EduPharma, Shire and Viforpharma. He received conference support or speaker\u2019s fee by Angelini and EduPharma. He is\/has been involved in clinical trials conducted by Roche, Lundbeck, Shire & Viforpharma. He received royalities from Oxford University Press and Giunti OS. The present work is unrelated to the above grants and relationships.ICKW: Prof. Wong reports grants from European Union FP7 programme, during the conduct of the study; grants from Shire, grants from Janssen-Cilag, grants from Eli-Lily, grants from Pfizer, outside the submitted work; and Prof Wong was a member of the National Institute for Health and Clinical Excellence (NICE) ADHD Guideline Group and the British Association for Psychopharmacology ADHD guideline group and acted as an advisor to Shire.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"327"}}